AN2 Therapeutics, Inc. is a California-based global health biopharmaceutical company focused on bringing the power of modern biomedical and drug development
Location: United States
Employees: 11-50
Total raised: $202M
Founded date: 2017
Investors 4
| Date | Name | Website |
| - | BioRock Ve... | biorockven... |
| - | Flucas Ven... | flucasvc.c... |
| 09.01.2022 | RA Capital... | racap.com |
| - | Adjuvant C... | adjuvantca... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 09.03.2026 | - | $40M | Commodore ... |
| 15.08.2023 | - | $70M | - |
| 07.01.2022 | Series B | $80M | RA Capital... |
| 21.11.2019 | Series A | $12M | - |
Mentions in press and media 8
| Date | Title | Description |
| 09.03.2026 | AN2 Therapeutics: $40 Million Private Placement Financing Announced | AN2 Therapeutics announced that it has entered into a securities purchase agreement for a private placement expected to generate approximately $40 million in gross proceeds before deducting placement agent fees and other expenses. The finan... |
| 22.03.2024 | Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results | Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational strategy Integrating R&D, manufacturing and commercial upsides by acquiring fu... |
| 15.08.2023 | AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock | - |
| 29.09.2022 | NIH Awards Contract to AN2 Therapeutics Valued Up to $17.8 Million | Non-dilutive funding will drive synergies with existing epetraborole development program for NTM lung disease Award leverages AN2 Therapeutics expertise and commitment to address urgent unmet global health needs Work could help address U.S.... |
| 07.01.2022 | AN2 Therapeutics Closes $80M Series B Financing | AN2 Therapeutics, Inc., a Menlo Park, CA-based clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases, completed an $80m Series B redeemable convertible preferred stock f... |
| 21.11.2019 | AN2 Therapeutics Secures $12M Series A | MENLO PARK, CA, AN2 Therapeutics today announced that it has raised $12 million in a Series A financing. >> Click here for more funding data on AN2 Therapeutics >> To export AN2 Therapeutics funding data to PDF and Excel, cl... |
| 21.11.2019 | AN2 Therapeutics Raises $12M in Series A Funding | AN2 Therapeutics, Inc., a Menlo Park, Calif.-based biopharmaceutical company focused on the research, development, and commercialization of novel medicines targeting infectious diseases, raised $12m in Series A financing. The round was led ... |
| - | AN2 Therapeutics’ IPO raises $69M to take antibiotic from Pfizer into pivotal test | Economic concerns have halted or at least delayed the plans of many companies to go public, but one biotech is braving the financial tumult, raising $69 million from its IPO to fund a pivotal test of a novel antibiotic licensed from Pfizer.... |